154 related articles for article (PubMed ID: 37029988)
1. Bone Metastases Detection in Patients with Breast Cancer: Does Bone Scintigraphy Add Information to PET/CT?
Cristo Santos J; Henriques Abreu M; Seoane Santos M; Duarte H; Alpoim T; Próspero I; Sousa S; Henriques Abreu P
Oncologist; 2023 Aug; 28(8):e600-e605. PubMed ID: 37029988
[TBL] [Abstract][Full Text] [Related]
2. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic performance of (18)F-fluorodeoxyglucose PET/CT and bone scintigraphy in breast cancer patients with suspected bone metastasis.
Niikura N; Hashimoto J; Kazama T; Koizumi J; Ogiya R; Terao M; Oshitanai R; Morioka T; Tsuda B; Okamura T; Saito Y; Iwaisako K; Iwamoto T; Hayashi N; Imai Y; Tokuda Y
Breast Cancer; 2016 Jul; 23(4):662-7. PubMed ID: 26037335
[TBL] [Abstract][Full Text] [Related]
4. Comparison of (18) F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma.
Hurley C; McCarville MB; Shulkin BL; Mao S; Wu J; Navid F; Daw NC; Pappo AS; Bishop MW
Pediatr Blood Cancer; 2016 Aug; 63(8):1381-6. PubMed ID: 27082077
[TBL] [Abstract][Full Text] [Related]
5. Significance of hormone receptor status in comparison of 18F -FDG-PET/CT and 99mTc-MDP bone scintigraphy for evaluating bone metastases in patients with breast cancer: single center experience.
Teke F; Teke M; Inal A; Kaplan MA; Kucukoner M; Aksu R; Urakci Z; Tasdemir B; Isikdogan A
Asian Pac J Cancer Prev; 2015; 16(1):387-91. PubMed ID: 25640386
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy.
Hansen JA; Naghavi-Behzad M; Gerke O; Baun C; Falch K; Duvnjak S; Alavi A; Høilund-Carlsen PF; Hildebrandt MG
PLoS One; 2021; 16(11):e0260066. PubMed ID: 34793550
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of 18F-FDG-PET/CT vs Bone Scintigraphy in Treatment Response Assessment of Bone Metastases in Breast Cancer.
Al-Muqbel KM; Yaghan RJ
Medicine (Baltimore); 2016 May; 95(21):e3753. PubMed ID: 27227942
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of bone metastases detection in cancer patients: comparison between bone scintigraphy and whole-body FDG-PET.
Fujimoto R; Higashi T; Nakamoto Y; Hara T; Lyshchik A; Ishizu K; Kawashima H; Kawase S; Fujita T; Saga T; Togashi K
Ann Nucl Med; 2006 Jul; 20(6):399-408. PubMed ID: 16922468
[TBL] [Abstract][Full Text] [Related]
10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
11. [18F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy.
Hildebrandt MG; Gerke O; Baun C; Falch K; Hansen JA; Farahani ZA; Petersen H; Larsen LB; Duvnjak S; Buskevica I; Bektas S; Søe K; Jylling AM; Ewertz M; Alavi A; Høilund-Carlsen PF
J Clin Oncol; 2016 Jun; 34(16):1889-97. PubMed ID: 27001573
[TBL] [Abstract][Full Text] [Related]
12. 18F-fluorodeoxyglucose-positron emission tomography and bone scintigraphy for detecting bone metastases in patients with malignancies of the upper aerodigestive tract.
Kim MR; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
Oral Oncol; 2008 Feb; 44(2):148-52. PubMed ID: 17350879
[TBL] [Abstract][Full Text] [Related]
13. Detection of the Prostate Cancer Bone Metastases: Is It Feasible to Compare 18F-fluorocholine PET/CT, 18F-fluorodeoxyglucose PET/CT and 99mTc-methyl Diphosphonate Bone Scintigraphy?
Pietrzak AK; Czepczynski R; Wierzchoslawska E; Cholewinski W
Urol J; 2018 Sep; 15(5):242-247. PubMed ID: 29681049
[TBL] [Abstract][Full Text] [Related]
14.
Wondergem M; van der Zant FM; Knol RJJ; Burgers AMG; Bos SD; de Jong IJ; Pruim J
World J Urol; 2018 Jan; 36(1):27-34. PubMed ID: 29043431
[TBL] [Abstract][Full Text] [Related]
15. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?
Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence.
Pennant M; Takwoingi Y; Pennant L; Davenport C; Fry-Smith A; Eisinga A; Andronis L; Arvanitis T; Deeks J; Hyde C
Health Technol Assess; 2010 Oct; 14(50):1-103. PubMed ID: 21044553
[TBL] [Abstract][Full Text] [Related]
17. ¹⁸F-Fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy.
Bortot DC; Amorim BJ; Oki GC; Gapski SB; Santos AO; Lima MC; Etchebehere EC; Barboza MF; Mengatti J; Ramos CD
Eur J Nucl Med Mol Imaging; 2012 Nov; 39(11):1730-6. PubMed ID: 22949079
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic performance of
Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
[TBL] [Abstract][Full Text] [Related]
19. Inter-observer variability between readers in detection of bone metastases comparing different modalities; PET/CT, SPECT/CT and planar bone scintigraphy.
Bashank N; Hussein A; Mekawy M; Askar H
Nucl Med Commun; 2023 Jul; 44(7):604-612. PubMed ID: 37114413
[TBL] [Abstract][Full Text] [Related]
20. Bone metastases from breast cancer: associations between morphologic CT patterns and glycolytic activity on PET and bone scintigraphy as well as explorative search for influential factors.
Sugihara T; Koizumi M; Koyama M; Terauchi T; Gomi N; Ito Y; Hatake K; Sata N
Ann Nucl Med; 2017 Dec; 31(10):719-725. PubMed ID: 28864931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
